a person holding a round object in their hands
  • Partnership Enhances Education on New TB Screening Methods
  • QIAGEN and IPPA Support Safe Immigration Process
  • Focus on Interferon Gamma Release Assay for TB Screening

Germantown, Maryland — In a significant move to enhance tuberculosis (TB) screening globally, Qiagen has announced a partnership with the International Panel Physicians Association (IPPA).

This collaboration aims to educate panel physicians worldwide on the latest TB screening requirements, with a special focus on the new Interferon Gamma Release Assay (IGRA) requirements and their benefits for patients and healthcare providers.

The announcement follows recent updates by the U.S. Centers for Disease Control and Prevention (CDC) on new TB screening requirements for immigrants to the United States.

Qiagen and IPPA are committed to promoting the use of IGRA testing, such as Qiagen’s QuantiFERON-TB Plus.

This advanced testing method is essential for ensuring a safe immigration process and supporting the global fight against TB.

IPPA, a U.S.-based non-profit organization, comprises physicians authorized to conduct immigration medical evaluations by governments of countries that receive migrants, including the U.S., Australia, Canada, New Zealand, and the United Kingdom.

This partnership is expected to play a crucial role in disseminating knowledge about the updated screening methods and their implementation in the global healthcare community.

By Silvia Orfeo

Silvia Orfeo is a Sr. Politics and Economics Reporter at Nobot.News

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner